Deciphering the surgical treatment gap for drug-resistant epilepsy (DRE): A literature review.
Elena SolliNicole A ColwellIrene SayRebecca HoustonAnmol S JohalJayoung PakLuke TomyczPublished in: Epilepsia (2020)
Patients with drug-resistant epilepsy (DRE) rarely achieve seizure freedom with medical therapy alone. Despite being safe and effective for select patients with DRE, epilepsy surgery remains heavily underutilized. Multiple studies have indicated that the overall rates of surgery in patients with DRE have stagnated in recent years and may be decreasing, even when hospitalizations for epilepsy-related problems are on the rise. Ultimately, many patients with DRE who might otherwise benefit from surgery continue to have intractable seizures, lacking access to the full spectrum of available treatment options. In this article, we review the various factors accounting for the persistent underutilization of epilepsy surgery and uncover several key themes, including the persistent knowledge gap among physicians in identifying potential surgical candidates, lack of coordinated patient care, patient misconceptions of surgery, and socioeconomic disparities impeding access to care. Moreover, factors such as the cost and complexity of the preoperative evaluation, a lack of federal resource allocation for the research of surgical therapies for epilepsy, and difficulties recruiting patients to clinical trials all contribute to this multifaceted dilemma.
Keyphrases
- drug resistant
- minimally invasive
- coronary artery bypass
- multidrug resistant
- healthcare
- acinetobacter baumannii
- clinical trial
- surgical site infection
- case report
- mental health
- temporal lobe epilepsy
- randomized controlled trial
- risk assessment
- patients undergoing
- end stage renal disease
- study protocol
- percutaneous coronary intervention
- cystic fibrosis
- patient reported outcomes
- acute coronary syndrome
- atrial fibrillation
- peritoneal dialysis
- human health
- patient reported
- affordable care act